Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Pediatrics/Neonatology | Pulmonary/Respiratory Diseases | Family Medicine
Disease Category: Asthma (Pediatric)
Location: United States, FL
12 week dose ranging study to evaluate the efficacy and safety of Fluticasone Propionate Spiromax administered twice daily compared with placebo in adolescents and adults with persistent asthma uncontrolled on non-steroidal therapy
12 weeks study requiring 6 morning visits. Subjects should be without inhaled corticosteroids for 6 weeks prior to the screening visit.
Patient Inclustion Criteria:
Patient Exclusion Criteria:
CW ID: 180222
Date Last Changed:
July 19, 2013
Florina Shawwaf, site directorFlorida Center for Allergy and Asthma Research21150 Biscayne Blvd.
# 408Aventura, FL 33180Phone: 305-932-3252Fax: 305-933-0928
Florida Center for Allergy and Asthma Research
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2015 CenterWatch.